B of A Securities Downgrades F5 to Neutral
B of A Securities analyst Tal Liani downgrades F5 (NASDAQ:FFIV) from Buy to Neutral.
Citigroup Maintains Neutral on F5, Lowers Price Target to $170
Citigroup analyst Jim Suva maintains F5 (NASDAQ:FFIV) with a Neutral and lowers the price target from $210 to $170.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 326 stocks hit new 52-week lows.
Expert Ratings for F5
Analysts have provided the following ratings for F5 (NASDAQ:FFIV) within the last quarter:
62 Biggest Movers From Yesterday
Gainers
Tenon Medical, Inc. (NASDAQ: TNON) rose 350% to clsoe at $22.50 on Wednesday after the company priced its IPO at $5.00 per share.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
B of A Securities Maintains Buy on F5, Lowers Price Target to $240
B of A Securities analyst Tal Liani maintains F5 (NASDAQ:FFIV) with a Buy and lowers the price target from $265 to $240.
Piper Sandler Maintains Overweight on F5, Lowers Price Target to $197
Piper Sandler analyst James Fish maintains F5 (NASDAQ:FFIV) with a Overweight and lowers the price target from $227 to $197.
Recap: F5 Q2 Earnings
F5 (NASDAQ:FFIV) reported its Q2 earnings results on Tuesday, April 26, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
F5 beat estimated earnings by 5.97%, reporting an EPS of $2.13 versus an estimate of $2.01.